Key Highlights
- 6.1% was the gain in Evolent Health (NYSE:EVH) to USD 4.07 on October 7, 2026, published market data show, ahead of a 1.4% median gain for two named healthcare peers.
- USD 652.5 million of second quarter revenue, up 47% from USD 444.3 million, came with a net loss of USD 28.4 million and adjusted EBITDA of USD 28.1 million.
- USD 115.7 million of cash sat against USD 966.5 million of long-term Debt at quarter end, so debt was about 2.2 times the roughly USD 434 million market value, simple arithmetic.
- USD 4.56 million traded versus a typical USD 9.18 million full session, a thin tape that tempers how much weight the 6.1% rise deserves, and shares ended mid-range.
What Moved Evolent Shares on October 7
Evolent Health (NYSE:EVH) rose about 6.1% to USD 4.07 on October 7, 2026, according to published market data. Claritev (NYSE:CTEV) gained 2.5%. Phreesia (NYSE:PHR) added 0.2%, a 1.4% median for the pair, so the move was larger than the group. We found no company release, filing or analyst action dated October 7, so the advance reads as flow driven. Trading value was USD 4.56 million, about half the typical USD 9.18 million, and the stock finished near the middle of its session range. One quote page showed a USD 3.84 close on October 6, which would imply a gain nearer 6.0%, simple arithmetic. The latest real catalyst was the August 6, 2026 second quarter report, covered below.
The August 6 Report and the Margin Mechanism
In the company release of August 6, 2026, Evolent said second quarter Revenue rose 47% to USD 652.5 million as new Performance Suite arrangements, where it takes medical cost risk for health plans, ramped up. Revenue rose because it now books more premium-like flows, but those flows carry medical costs. The medical expense ratio was 95.3% versus 80.0% a year earlier, which squeezed profit. Net loss narrowed to USD 28.4 million from USD 51.1 million, while adjusted EBITDA fell to USD 28.1 million from USD 37.5 million. Management raised 2026 revenue guidance to USD 2.6 billion to USD 2.7 billion and set adjusted EBITDA at USD 120 million to USD 135 million.
Risks, Peers and What to Watch
The main risk is leverage. Long-term debt of USD 966.5 million dwarfs the cash balance, and the shares trade far below their 52-week high near USD 8.4 against a low of USD 2.10. Medical cost trends can swing results quickly under risk contracts. Management guided to 2027 revenue growth above 25% and adjusted EBITDA at or above USD 150 million at the midpoint, plus a new oncology Partnership covering about 1.5 million lives in 11 states, expected to launch in December 2026 and add about USD 300 million of annualized revenue. Third quarter results are estimated for about November 5, 2026, a date the company has not confirmed in our review.
Where Things Stand
Evolent Health's October 7 rise looks like a flow driven bounce rather than a response to news, because no company catalyst was found that day. The fundamentals remain mixed: fast revenue growth, narrowing net losses, but a higher medical expense ratio and heavy debt. Evolent Health (NYSE:EVH) shares are up about 4.8% year to date but down 3.4% over the past month, per the published figures, so one session settles little. The next hard evidence is the third quarter report, estimated for early November.






Please wait processing your request...